These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 26354886)

  • 21. Re: Prospective evaluation of operating characteristics of prostate cancer detection biomarkers: Y. Liang, D. P. Ankerst, N. S. Ketchum, B. Ercole, G. Shah, J. D. Shaughnessy, Jr., R. J. Leach and I. M. Thompson J Urol 2011; 185: 104-110.
    Catalona WJ
    J Urol; 2011 Nov; 186(5):2131-2; author reply 2132. PubMed ID: 21945513
    [No Abstract]   [Full Text] [Related]  

  • 22. Re: Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare: S. Loeb, H. B. Carter, S. I. Berndt, W. Ricker and E. M. Schaeffer J Urol 2013; 189: 867-870.
    Singh I; Gautam L
    J Urol; 2013 Oct; 190(4):1439-40. PubMed ID: 23886882
    [No Abstract]   [Full Text] [Related]  

  • 23. Commentary on: "Inherited DNA-repair gene mutations in men with metastatic prostate cancer." Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS. N Engl J Med. 2016 Aug 4;375(5):443-53.
    Lee BH
    Urol Oncol; 2017 Sep; 35(9):575-576. PubMed ID: 28789927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re: The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy I. M. Thompson, C. M. Tangen, D. P. Ankerst, C. Chi, M. S. Lucia, P. Goodman, H. Parnes and C. A. Coltman, Jr. J Urol 2008; 180: 544-547.
    Atmaca AF; Balbay MD
    J Urol; 2009 May; 181(5):2387-8. PubMed ID: 19303084
    [No Abstract]   [Full Text] [Related]  

  • 25. Re: Smaller prostate size predicts high grade prostate cancer at final pathology. M. R. Newton, S. Phillips, S. S. Chang, P. E. Clark, M. S. Cookson, R. Davis, J. H. Fowke, S. D. Herrell, R. Baumgartner, R. Chan, V. Mishra, J. D. Blume, J. A. Smith, Jr. and D. A. Barocas. J Urol 2010; 184: 930-937.
    Calışkan S
    J Urol; 2011 Apr; 185(4):1537-8; author reply 1538. PubMed ID: 21349547
    [No Abstract]   [Full Text] [Related]  

  • 26. Re: The Prostate Cancer Prevention Trial: design, biases and interpretation of study results. P. J. Goodman, I. M. Thompson, Jr., C. M. Tangen, J. J. Crowley, L. G. Ford and C. A. Coltman, Jr., J Urol, 175: 2234-2242, 2006.
    Walsh PC
    J Urol; 2006 Dec; 176(6 Pt 1):2744; author reply 2744. PubMed ID: 17085206
    [No Abstract]   [Full Text] [Related]  

  • 27. Re: the prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. C. G. Roehrborn, S. N. Gange, N. D. Shore, J. L. Giddens, D. M. Bolton, B. E. Cowan, B. T. Brown, K. T. McVary, A. E. Te, S. S. Gholami, P. Rashid, W. G. Moseley, P. T. Chin, W. T. Dowling, S. J. Freedman, P. F. Incze, K. S. Coffield, F. D. Borges and D. B. Rukstalis J Urol 2013;190:2161-2167.
    Gupta S; Singh V; Goel A
    J Urol; 2014 Jun; 191(6):1934-5. PubMed ID: 25405255
    [No Abstract]   [Full Text] [Related]  

  • 28. Re: the prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. C. G. Roehrborn, S. N. Gange, N. D. Shore, J. L. Giddens, D. M. Bolton, B. E. Cowan, B. T. Brown, K. T. McVary, A. E. Te, S. S. Gholami, P. Rashid, W. G. Moseley, P. T. Chin, W. T. Dowling, S. J. Freedman, P. F. Incze, K. S. Coffield, F. D. Borges and D. B. Rukstalis J Urol 2013;190:2161-2167.
    Mavuduru RS; Devana SK; Nayak B
    J Urol; 2014 Jun; 191(6):1934. PubMed ID: 24631348
    [No Abstract]   [Full Text] [Related]  

  • 29. Re: Validation of the Partin nomogram for prostate cancer in a national sample: J. B. Yu, D. V. Makarov, R. Sharma, R. E. Peschel, A. W. Partin and C. P. Gross J Urol 2010; 183: 105-111.
    Ozcan MF; Akbulut Z; Canda AE; Kilic M; Duran E; Balbay MD
    J Urol; 2010 Oct; 184(4):1571-2; author reply 1572-3. PubMed ID: 20732697
    [No Abstract]   [Full Text] [Related]  

  • 30. Reply by Authors.
    J Urol; 2015 Dec; 194(6):1826. PubMed ID: 26354889
    [No Abstract]   [Full Text] [Related]  

  • 31. Re: Effectiveness of antibiotics given to asymptomatic men for an increased prostate specific antigen. S. Baltaci, E. Suer, A. H. Haliloglu, M. I. Gokce, A. H. Elhan and Y. Beduk. J Urol 2009; 181: 128-132.
    Eggener SE; Raman JD
    J Urol; 2009 Jul; 182(1):396-7. PubMed ID: 19467675
    [No Abstract]   [Full Text] [Related]  

  • 32. Re: Monique J. Roobol, Fritz H. Schröder, Pim van Leeuwen, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010;58:475-81.
    Connolly D; Hutton R; Keane PF
    Eur Urol; 2011 Mar; 59(3):e9; author reply e10-1. PubMed ID: 21145647
    [No Abstract]   [Full Text] [Related]  

  • 33. Re: Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer when the Prostate Specific Antigen is in the Diagnostic Gray Zone: .: A. Aminsharifi, L. Howard, Y. Wu, A. De Hoedt, C. Bailey, S. J. Freedland and T. J. Polascik J Urol 2018; 200: 758-766.
    Wang CS; Jhan JH; Li CC
    J Urol; 2019 Mar; 201(3):627-628. PubMed ID: 30759714
    [No Abstract]   [Full Text] [Related]  

  • 34. Re: Clinical performance of serum isoform (-2)proPSA (p2PSA) and its derivatives, namely %p2PSA and PHI (Prostate Health Index) in men younger than 60 years of age: results from a multicentric European study.
    Taneja SS
    J Urol; 2014 Aug; 192(2):421. PubMed ID: 25034991
    [No Abstract]   [Full Text] [Related]  

  • 35. Re: The 20-core prostate biopsy protocol--a new gold standard?: V. Ravery, S. Dominique, X. Panhard, M. Toublanc, L. Boccon-Gibod and L. Boccon-Gibod. J Urol 2008; 179: 504-507.
    Serefoglu EC; Ozdemir AT; Balbay MD
    J Urol; 2008 Nov; 180(5):2256-7. PubMed ID: 18804806
    [No Abstract]   [Full Text] [Related]  

  • 36. Novel biomarkers and advanced imaging modalities in the early detection of prostate cancer.
    Parsons JK
    J Urol; 2015 Apr; 193(4):1084-5. PubMed ID: 25596362
    [No Abstract]   [Full Text] [Related]  

  • 37. Re: A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. T. Wolters, M. J. Roobol, P. J. van Leeuwen, R. C. van den Bergh, R. F. Hoedemaeker, G. J. van Leenders, F. H. Schröder and T. H. van der Kwast. J Urol 2011;185: 121-125.
    Moore CM; Klotz L; Emberton M
    J Urol; 2011 Sep; 186(3):1158-9; author reply 1159. PubMed ID: 21784490
    [No Abstract]   [Full Text] [Related]  

  • 38. Re: Early detection of prostate cancer: AUA guideline: H. B. Carter, P. C. Albertsen, M. J. Barry, R. Etzioni, S. J. Freedland, K. L. Greene, L. Holmberg, P. Kantoff, B. R. Konety, M. H. Murad, D. F. Penson and A. L. Zietman J Urol 2013; 190: 419-426.
    Moul JW; Walsh PC; Rendell MS; Lynch HT; Leslie SW; Kosoko-Lasaki O; Fitzgibbons WP; Powell I; D'Amico AV; Catalona WJ
    J Urol; 2013 Sep; 190(3):1134-7. PubMed ID: 23871525
    [No Abstract]   [Full Text] [Related]  

  • 39. Re: Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era: A. S. Kibel, J. P. Ciezki, E. A. Klein, C. A. Reddy, J. D. Lubahn, J. Haslag-minoff, J. O. Deasy, J. M. Michalski, D. Kallogjeri, J. F. Piccirillo, D. M. Rabah, C. Yu, M. W. Kattan And A. J. Stephenson; J Urol 2012; 187: 1259-1265.
    Stenmark MH; Hamstra DA
    J Urol; 2012 Dec; 188(6):2438-9; author reply 2439-40. PubMed ID: 23088984
    [No Abstract]   [Full Text] [Related]  

  • 40. Re: a prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. I.D.C. Mitchell, B.L. Croal, A. Dickie, N.P. Cohen and I. Ross. J Urol, 165: 1549-1553, 2001.
    Stephan C; Jung K; Schnorr D; Lein M; Sinha P; Loening SA
    J Urol; 2002 Jan; 167(1):259-60. PubMed ID: 11743329
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.